Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

Roger J.M. Brüggemann; Jan Willem C. Alffenaar; Nicole M.A. Blijlevens; Eliane M. Billaud; Jos G.W. Kosterink; Paul E. Verweij; David M. Burger

doi:10.1086/598327

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

Roger J.M. Brüggemann, Jan Willem C. Alffenaar, Nicole M.A. Blijlevens, Eliane M. Billaud, Jos G.W. Kosterink, Paul E. Verweij, David M. Burger

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

360 Citaten (Scopus)

Samenvatting

There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.

Originele taal-2	Engels
Pagina's (van-tot)	1441-1458
Aantal pagina's	18
Tijdschrift	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	48
Nummer van het tijdschrift	10
DOI's	https://doi.org/10.1086/598327
Status	Gepubliceerd - 15 mei 2009
Extern gepubliceerd	Ja

Toegang tot document

10.1086/598327

Citeer dit

Brüggemann, R. J. M., Alffenaar, J. W. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009). Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 48(10), 1441-1458. https://doi.org/10.1086/598327

@article{cf003344d993439d82e734996fabdfbc,

title = "Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents",

abstract = "There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.",

author = "Br{\"u}ggemann, {Roger J.M.} and Alffenaar, {Jan Willem C.} and Blijlevens, {Nicole M.A.} and Billaud, {Eliane M.} and Kosterink, {Jos G.W.} and Verweij, {Paul E.} and Burger, {David M.}",

year = "2009",

month = may,

day = "15",

doi = "10.1086/598327",

language = "English",

volume = "48",

pages = "1441--1458",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1537-6591",

publisher = "Oxford University Press",

number = "10",

}

Brüggemann, RJM, Alffenaar, JWC, Blijlevens, NMA, Billaud, EM, Kosterink, JGW, Verweij, PE & Burger, DM 2009, 'Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 48, nr. 10, blz. 1441-1458. https://doi.org/10.1086/598327

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. / Brüggemann, Roger J.M.; Alffenaar, Jan Willem C.; Blijlevens, Nicole M.A. et al.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 48, Nr. 10, 15.05.2009, blz. 1441-1458.

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

TY - JOUR

T1 - Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

AU - Brüggemann, Roger J.M.

AU - Alffenaar, Jan Willem C.

AU - Blijlevens, Nicole M.A.

AU - Billaud, Eliane M.

AU - Kosterink, Jos G.W.

AU - Verweij, Paul E.

AU - Burger, David M.

PY - 2009/5/15

Y1 - 2009/5/15

N2 - There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.

AB - There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.

UR - http://www.scopus.com/inward/record.url?scp=65549159077&partnerID=8YFLogxK

U2 - 10.1086/598327

DO - 10.1086/598327

M3 - Review article

C2 - 19361301

AN - SCOPUS:65549159077

SN - 1537-6591

VL - 48

SP - 1441

EP - 1458

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - 10

ER -

Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit